Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16158862 | 0.88 | TSHR (0.44) | TSHRTAAR1LMNAHTTSLC6A2 | |
| SCHEMBL16158879 | 0.88 | TSHR (0.44) | TSHRTAAR1LMNAHTTSLC6A2 | |
| SCHEMBL18499302 | 0.88 | TSHR (0.44) | TSHRTAAR1LMNAHTTSLC6A2 | |
| SCHEMBL16625047 | 0.88 | TSHR (0.44) | TSHRTAAR1LMNAHTTSLC6A2 | |
| SCHEMBL24572017 | 0.88 | TSHR (0.61) | TSHRTAAR1LMNASLC6A2HTR1A | |
| SCHEMBL13941992 | 0.88 | TSHR (0.61) | TSHRTAAR1LMNASLC6A2HTR1A | |
| SCHEMBL2386075 | 0.88 | TSHR (0.61) | TSHRTAAR1LMNASLC6A2HTR1A | |
| SCHEMBL24215035 | 0.88 | TSHR (0.61) | TSHRTAAR1LMNASLC6A2HTR1A | |
| SCHEMBL9679098 | 0.88 | TSHR (0.61) | TSHRTAAR1LMNASLC6A2HTR1A | |
| SCHEMBL22992639 | 0.85 | TSHR (0.41) | TSHRTAAR1LMNAHTTSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130339-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-06 | — | — | US | disclosed |
| WO-2018137573-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-08-02 | — | — | WO | disclosed |
| CN-108290879-A | Heteroaryl compound and application thereof as IRAK inhibitor | 默克专利有限公司 | 2018-07-17 | — | — | CN | disclosed |
| US-5621133-A | PREPARING A 1-(3,4-DIALKOXYPHENYL),3-HYDROXYALKANE(C6-C12) BY EPOXIDIZING A HALO DERIVATIVE WITH A BASE FOLLOWED BY DECYCLICIZING WITH AN ORGANOMETALLIC COMPOUND IN A SOLVENT; NAPHTHYLENES, ISOCHROMENES AND ISOTHIOCHROMENES | DENINNO MICHAEL P (US) | 1997-04-15 | — | — | US | disclosed |
| US-5591884-A | PROTECTED HYDROXYALKYLCATECHOL INTERMEDIATES | ABBOTT LABORATORIES (US) | 1997-01-07 | — | — | US | disclosed |
| WO-1996038435-A1 | DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1996-12-05 | — | — | WO | disclosed |
| EP-0474767-B1 | DOPAMINE AGONISTS | ABBOTT LAB (US) | 1996-02-21 | — | — | EP | disclosed |
| EP-0474767-A4 | DOPAMINE AGONISTS | — | 1992-07-08 | — | — | EP | disclosed |
| EP-0474767-A1 | DOPAMINE AGONISTS. | ABBOTT LAB (US) | 1992-03-18 | — | — | EP | disclosed |
| WO-1990015056-A1 | DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1990-12-13 | — | — | WO | disclosed |
| EP-0302599-A2 | Bicyclo-octane and bicyclo-nonane derivatives, processes for their preparation and their use as herbicides | HER MAJESTY THE QUEEN IN RIGHT OF NEW ZEALAND, DEPARTMENT OF SCIENTIFIC AND INDUSTRIAL RESEARCH, CHEMISTRY DIVISON (NZ) | 1989-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130339-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | TSHR 4833/4885TAAR1 4550/4885LMNA 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.